Biogen Inc. provided earnings guidance for the full year of 2024. For the year, the company continues to expect total revenue to decline by a low- to mid-single digit percentage vs. 2023 and expect core pharmaceutical revenue (product revenue + LEQEMBI) to be flat vs.

2023 as further declines in multiple sclerosis product revenue are expected to be offset by increases in revenue from new product launches. Operating income to grow at a low-double digit percentage. This is expected to be driven by improved cost of sales as a percentage of revenue, as well as lower operating expenses as a result of the Company's Fit for Growth program.